Interview: President of Jacobs Company
>> i.b.m. reported earnings after the close saying that third-quarter revenue was 21.5 million, shy of what analysts had been looking for. if you lock at the profit per share, excluding certain items, coming in at $1.26 per share, stronger than analysts were looking for, looking for $1.13 on average. the total margin, 30.6%, a key number for investors. we’ll find out why when we’re joined by john jacobs, president of jacobs and company, managing $150 million for his firm including 80,000 shares of i.b.m. i was going over some of those numbers with you during the break and you had a positive reaction. what is your reaction to this report?
>> the key for us this week is we wanted to see gross margins above 40%. we felt if they did this with the strong bookings that i.b.m. has, even knowing the revenues were lower primarily because of the lenovo sale on the p.c. side, this tells us they’re focussing on their strength and it is the strong bookings coming and the 40% gross margin, they’re starting to really get it down, a key quarter for i.b.m.
>> they sold that p.c. business, it was not profitable. it got so much press, they had an earnings miss and they’ve been restructuring. how significant is it that the sales are lighter than analysts on average were looking for?
>> i think you’ll find most analysts thought the revenue number might be softer. because what’s happened here is that a lot of the bookings have come late in the quarter. the key will be when we get to the conference call in a few minutes when they begin to start in terms of the quality of what’s going forward. i think you’ll hear bullish remarks because what’s happening, their approach to everything, they bring the c.p.a.’s, consultants in and they take the expertise, in house that the companies are working with and do the hardware, software support, everything. it’s really catching on. you’ll also see as we dig deep in the report, they should have over 50% of their revenues coming, now, just from the service side and that’s also significant.
>> and the company saying as part of this report that the services backlog is $113 billion. what does that indicate to you, then, about how strong future quarters may be? >> we have felt tech should have a very strong demand coming in the fourth quarter. this confirms that. not only does it confirm it here, i.b.m. is the leader, number one and number two in almost all market segment where is they are and i think what you’re seeing here is they’ve had to fight back. they have had some missteps and i think finally you’re seeing a ship on the right court and -- course and not only should we see a strong quarter and unless the worldwide economy gets really weak, i think we’ll see a strong 2006, as well, for tech.
>> you have about 80,000 shares for i.b.m. what will you do in extended trade tonight or tomorrow morning?
>> we really to look to do, as the market moves, we’ll see the response from investors and the key will be, we like a covered call strategy and it’s very possible, depending on the pop i.b.m. gets tomorrow --
>> explain to us what a covered call strategy is?
>> what we will do, we will go out to the marketplace, probably to january, and give an investor three months. we will look to give someone the right to buy our shares at $85 or $90 and we will go to january of 2006 for that to be when that contract expires. what will happen, they will pay us for that right, which will give us protection and it will be incomead at the end of the contract but i think with this report we may see a good 5% to 7% which givss us―gives us good downside. the market is nervous overall but this could be a good kick into the fourth quarter.
>> you think a 5% to 7% pop potentially on the shares. that’s interesting, those shares down 16% year to date but 24 buys on the stock, very few holds. why is there such a disconnect between what the analyst community says and how investors have reacted?
>> i think there’s been a disconnect because of the misses they’ve had. what this has to do is bring confidence back to management. because what has happened here, you’ve had two or three significant areas over the last year where analysts and investors are just scratching their heads saying, you know, what’s really happening? they’re talking about cutting costs, what are they doing? well, just as an example, we’ve seen in europe, without a doubt, they’re ahead of their head count in terms of becoming much more efficient on all sides here. we’ve seen over the last month tremendous movements where everything should be going right for i.b.m. and i think this report should give confidence back to the investor community and back to tech, where i.b.m. can possibly step up again here and get their place in terms of leaders in market share.
>> briefly, given the report, what’s the biggest risk to owning the shares?
>> i think the biggest risk is really the worldwide economy. i mean, always technology, but the worldwide economy, if things start to slow, but the key here, spending with i.t. today is so discretionary. companies are making the move to this now because they want to be more efficient and i think the risks are lower than they’ve been for probably a year and a half.
>> john, thanks so much for joining us. john jacobs joining us in our new york studio. we’ll take a quick break. when we come back, refco futures brokerage business about to be scooped up by a private equity firm run by a former goldman sachs partner. our allan dodds frank will have the latest on a troubled company.
点击播报
Listen Market briefing --- Ellen (slow)
IBM --- Brett (slow)
J & J --- Suzanne (slow)
stocks rose today as shares of general motors went higher on news of an accord with the u.a.w. over healthcare costs. still, benchmark indexes held back for much of the day on another advance for energy prices as well as concerns about inflation. here’s how the markets settled today, the dow up 60 points, 10,348. shares of g.m. along with altria giving the biggest boost to the dow. the s&p up 3.5 points and the nasdaq rising by five. we’ll have more on the markets in a few moments’ time. first up, i.b.m., it is the first big technology company to report earnings this week. the company elected to bring back profit earns overseas last quarter and costs related to that pushed down net income. let’s get more details on that report from brett gehrig. hi, brett.
>> i.b.m. recorded tax costs of about $525 million after taking advantage of a tax break to return $9 billion in earnings. net income for the quarter came in at $1.52 billion or 94 cents a share. excluding that cost, profit per share was $1.26, far exceeding the average estimate among analysts. top-line growth, though, was not as strong as analysts had hoped. revenue at i.b.m.’s hardware services unit plunged 32% from the year-ago period to 5.1%. this quarter is the first without the p.c. unit that i.b.m. sold to lenovo group in may for $1.25 billion. analysts say i.b.m. is working to build market share in other businesses.
>> they have a competitive lineup outside the main frame and the rest of the server, have seen very strong growth in the low end of the business, in the blade server market . and the recent offering around a new chip architecture and higher end of the server market has been pretty well received.
>> a new main frame compute that―computer that went on sale bolstered revenue at i.b.m.’s hardware unit. software revenue totalled $3.8 billion, a gain of 5%. global services revenue increased slightly from a year ago. i.b.m. signed $11 billion worth of services contracts in the quarter. we’ll get a better idea of how the technology industry fared last quarter when other bellwethers report earnings later this week. intel and yahoo announced their latest results tomorrow and google will release its profit report on friday. back to you.
>> brett, thanks so much. we did have several earnings reports or forecasts come out, as well, after the close today. chiron saying full-year earnings will be lower than the company forecast. and that’s because it will produce fewer doses of its flu i have ron―viron influenza vaccine. the number of doses will be lower than previously forecast for the 2005-2006 flu season because of delays as the company resolves manufacturing issues. the company did not provide a new forecast. also after the close, you had novellus out with earnings. what novellus said is that it did earn 21 cents per share, if you exclude items. on that basis, matching what analysts were looking for. novellus saying fourth-quarter sales will be down 5% to 10% from the third quarter. novellus saying fourth-quarter earnings per share of 15 to 17 cents a share, if you exclude costs. novellus makes machines used in making semiconductors and in late august, the company had narrowed its profit and sales forecast for the third quarter that it reported today. as chipmakers remain conservative about buying new equipment because of high oil prices, novellus faces increased competition and industry-wide price cuts. shares down about 12% so far this year. and let’s get earnings after the close, as well, from rambus. the company said that profit was up 40% to 14 cents a share for the third quarter. sales, however, were down 7.1% to $36.1 million. the profit number up 40% to 14 cents a share. the average analyst estimates had been two cents a share. rambus, in terms of background, it’s a company that sells chip designs. it receives royalties on patents, it says, cover fundamentals of all memory chip design. the company has said sales will fall as it loses licensing payments from samsung. also, as other company agreements expire and come up for renegotiation. shares have lost about half their value so far this year. as we look ahead to earnings due later this week, johnson & johnson set to report tomorrow. the company’s pending acquisition of the heart device maker, guidant, is the main focus for investors. analysts surveyed estimate johnson & johnson’s revenue will rise to 86 cents a share. sales forecast to rise 8% to $12.5 billion. suzanne o’halloran joins us with more specifics on the quarter.
>> j&j’s profit growth next year is expected to be half what it was in 2003 and with few blockbuster drugs in the pipeline, analysts say j&j’s medical device unit is a bonus for the company. the drug-coated heart stent probably regained market share against rival boston scientific. research indicates j&j’s stent outperforming the competing product. investor jake dollarhyde says the medical device unit is helping stem the slowdown in medical pharmaceuticals.
>> medical products and over-the-counter products like tylenol, bandaids, slenda -- splenda, are really helping bridge the gap between falling, slowing pharmaceutical sales and other high-growth sales medical products making j&j attractive to value and growth investors.
>> still, some investors and analysts say the $25 billion j&j is paying to buy guidant is too much. following j&j’s proposed acquisition of guidant, they have recalled defective pacemakers and defibrillators. although u.b.s. analyst kenneth wheatley says the guidant deal will erase 30 cents off next year’s earnings, he calls j&j’s one of the best portfolio managers in healthcare and sees the deal broadening the company’s product scope with shares rising 25% in the next year. the pharmaceutical unit, which generated 46% of sales last year is, struggling. sales likely grew just 1% in the latest quarter. j&j’s best selling aniqueia drug, procrit is, losing sales to amgen’s rival drug. medicaid pressures may hurt sales of its number two drug for schizophrenia and its painkiller probably lost 2/3 of sales to generics. patents on drugs for attention deficit disorder and incontinence expire next year and f.d.a. concerns may delay approval for a drug for premature ejaculation by as long as nine months. shares of j&j lost in today’s session.
>> the swiss pharmaceutical company, serono, agreed to settle civil and criminal charges for promoting of its aids drug.
>> it put its desire to sell more ser oftim above interests of the public and the country has a system of evaluating and approving the use of drugs through the f.d.a. and the health of americans depends upon the pharmaceutical industry adhering to that system and acting responsibly. serono abused that system.
>> the company pled guilty to acquisitions it conspired with a drugmaker in promoteing a product not endorsed by the food and drug administration. an executive change on tell you about over at nortel networks. the company, the largest north american telephone equipment maker named a former motorola official, mike zafirovski, as chief executive, doing this to help win back customers who had been driven away by nortel’s accounting fraud. zafirovski quit as motorola’s president in january after he was passed over for the top spot there. at nortel, he will succeed bill owens as president and c.e.o., beginning november 15. owens is handing over the reins after spending 18 months unwinding accounting misstatements that dated back to 1999 and as you see, shares ending the day higher by 5.5%. an update to tell you about, the auto parts maker, delphi. chief executive steve miller says he will cut his salary to a dollar a year from january 1 until the company exits from bankruptcy. the move comes in response to union’s criticism of miller for increasing executive severance plans. delphi president rodney o’neill will take a 20% reduction in base pay and about 20 other executives will take cuts of 10%. miller said he will keep a $3 million signing bonus he received when he joined delphi in january. that original deal with miller put his annual salary at $1.5 million. we’ll take a quick break. when we return, we’ll have more on the i.b.m. earnings. checking the stock right now in extended hours, up 1.3%. we’ll be right back.